Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.30 |
| ▸ | CES1 | P23141 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3355714 | 1.00 | FFAR3 (0.33) | FFAR3EP300CYP2C9CES2CES1 | |
| SCHEMBL3355710 | 1.00 | FFAR3 (0.33) | FFAR3EP300CYP2C9CES2CES1 | |
| SCHEMBL5902788 | 0.88 | CYP2C9 (0.35) | FFAR3CYP2C9 | |
| SCHEMBL1902372 | 0.83 | CES2 (0.44) | FFAR3EP300CYP2C9CES2CES1 | |
| SCHEMBL10818403 | 0.82 | GLO1 (0.34) | CYP2C9CES1 | |
| SCHEMBL10818408 | 0.82 | GLO1 (0.34) | CYP2C9CES1 | |
| SCHEMBL25242898 | 0.80 | TSHR (0.32) | — | |
| SCHEMBL28995635 | 0.80 | TSHR (0.32) | — | |
| SCHEMBL22531952 | 0.80 | ABAT (0.30) | — | |
| SCHEMBL27190835 | 0.80 | LDHA (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111094292-A | Pyrazolo [1,5a ] pyrimidine derivatives as IRAK4 modulators | 豪夫迈·罗氏有限公司 | 2020-05-01 | — | — | CN | disclosed |
| US-20170291890-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. | 2017-10-12 | — | — | US | disclosed |
| EP-3194377-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2017-07-26 | — | — | EP | disclosed |
| WO-2016044666-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | Epizyme, Inc. (US) | 2016-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291890-A1 | HETEROCYCLE SUBSTITUTED AMINO-PYRIDINE COMPOUNDS AND METHODS OF USE THEREOF | HCCS, TP53, NME2 | FFAR3 3575/4885EP300 706/4885CYP2C9 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.